Compare Lam Research Corporation (LRCX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Medpace Holdings Inc — how do they compare? Lam Research Corporation trades at $320.89 (market cap $402.68B), while Medpace Holdings Inc trades at $624 (market cap $15.18B). The key difference: Lam Research Corporation is far larger — about 26.5× Medpace Holdings Inc's market cap, and Lam Research Corporation pays a 0.32% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| LRCX | MEDP | |
|---|---|---|
Market Cap | $402.68B | $15.18B |
Sector | Technology | Technology |
52-Week High | $433.33 | $620.59 |
52-Week Low | $94.84 | $393.42 |
Enterprise Value | $401.67B | $14.65B |
Dividend Yield | 0.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $322.00, up 2.78% today, with a bullish technical signal despite mixed moving averages. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $1.47 surpassing the $1.36 forecast. Revenue grew to $18.44B in 2025, and net income margin improved to 30.94%. Analysts maintain a strong buy consensus with a $396.06 price target, though high valuation multiples like a P/E of 57.99 and sector volatility present risks.
Outlook remains positive driven by AI-related semiconductor demand and operational efficiency, but investors face risks from elevated valuations and industry cyclicality. The stock's proximity to the $319 resistance level suggests near-term momentum could hinge on Q2 2026 earnings results against a $1.69 EPS expectation.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
